SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-244795
Filing Date
2021-08-12
Accepted
2021-08-12 16:41:10
Documents
18
Period of Report
2021-08-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d60776d8k.htm   iXBRL 8-K 29536
2 EX-1.1 d60776dex11.htm EX-1.1 165749
3 EX-5.1 d60776dex51.htm EX-5.1 10582
4 EX-99.1 d60776dex991.htm EX-99.1 9168
8 GRAPHIC g60776g0812084540504.jpg GRAPHIC 2838
9 GRAPHIC g60776g0812230045718.jpg GRAPHIC 1649
10 GRAPHIC g60776g47o98.jpg GRAPHIC 6155
  Complete submission text file 0001193125-21-244795.txt   406272

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fulc-20210811.xsd EX-101.SCH 2895
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20210811_lab.xml EX-101.LAB 18123
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20210811_pre.xml EX-101.PRE 11407
11 EXTRACTED XBRL INSTANCE DOCUMENT d60776d8k_htm.xml XML 3355
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 211168256
SIC: 2834 Pharmaceutical Preparations